Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGAV | P06756 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7675724 | 0.98 | DRD2 (0.49) | KDM4EHSD17B10CYP3A4CYP2C9HPGD | |
| Trifluoroacetic Acid SCHEMBL5858033 | 0.94 | DRD2 (0.46) | KDM4EHSD17B10CYP3A4CYP2C9HPGD | |
| SCHEMBL2843026 | 0.89 | DRD3 (0.56) | DRD2ADRA1ADRD3HTR1AITGB3 | |
| Trifluoroacetic Acid SCHEMBL5856786 | 0.83 | DRD2 (0.53) | DRD2ADRA1ADRD3ITGB3ITGAV | |
| SCHEMBL7675733 | 0.81 | DRD2 (0.47) | DRD2ADRA1ADRD3ITGB3ITGAV | |
| SCHEMBL2833676 | 0.78 | KDM4E (0.42) | KDM4EHSD17B10CYP3A4CYP2C9HPGD | |
| SCHEMBL2833670 | 0.78 | KDM4E (0.42) | KDM4EHSD17B10CYP3A4CYP2C9HPGD | |
| SCHEMBL4394126 | 0.77 | ITGB3 (0.64) | ITGB3ITGAVITGB5 | |
| SCHEMBL243759 | 0.77 | ITGB3 (0.63) | HSD17B10HPGDITGB3ITGAVITGB5 | |
| SCHEMBL2037116 | 0.76 | ITGB3 (0.70) | ITGB3ITGAVITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | claimed |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| US-7119098-B2 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6933304-B2 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1289983-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | disclosed |
| WO-2001096334-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | KDM4E 3438/4885HSD17B10 1876/4885CYP3A4 1713/4885 |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | KDM4E 4380/4885HSD17B10 1806/4885CYP3A4 4143/4885 |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | ITGA5, ITGA2B, ITGAV | KDM4E 3466/4885HSD17B10 1734/4885CYP3A4 1942/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | KDM4E 4380/4885HSD17B10 1806/4885CYP3A4 4143/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | KDM4E 4380/4885HSD17B10 1806/4885CYP3A4 4143/4885 |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | ITGA5, ITGB7, ITGA2B | KDM4E 4382/4885HSD17B10 1402/4885CYP3A4 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.